Literature DB >> 34340167

Effectiveness and implementability of state-level naloxone access policies: Expert consensus from an online modified-Delphi process.

Rosanna Smart1, Sean Grant2.   

Abstract

BACKGROUND: Naloxone distribution, a key global strategy to prevent fatal opioid overdose, has been a recent target of legislation in the U.S., but there is insufficient empirical evidence from causal inference methods to identify which components of these policies successfully reduce opioid-related harms. This study aimed to examine expert consensus on the effectiveness and implementability of various state-level naloxone policies.
METHODS: We used the online ExpertLens platform to conduct a three-round modified-Delphi process with a purposive sample of 46 key stakeholders (advocates, healthcare providers, human/social service practitioners, policymakers, and researchers) with naloxone policy expertise. The Effectiveness Panel (n = 24) rated average effects of 15 types of policies on naloxone pharmacy distribution, opioid use disorder (OUD) prevalence, nonfatal opioid-related overdoses, and opioid-related overdose mortality. The Implementation Panel (n = 22) rated the same policies on acceptability, feasibility, affordability, and equitability. We compared ratings across policies using medians and inter-percentile ranges, with consensus measured using the RAND/UCLA Appropriateness Method Inter-Percentile Range Adjusted for Symmetry technique.
RESULTS: Experts reached consensus on all items. Except for liability protections and required provision of education or training, experts perceived all policies to generate moderate-to-large increases in naloxone pharmacy distribution. However, only three policies were expected to yield substantive decreases on fatal overdose: statewide standing/protocol order, over-the-counter supply, and statewide "free naloxone." Of these, experts rated only statewide standing/protocol orders as highly affordable and equitable, and unlikely to generate meaningful population-level effects on OUD or nonfatal opioid-related overdose. Across all policies, experts rated naloxone prescribing mandates relatively lower in acceptability, feasibility, affordability, and equitability.
CONCLUSION: Experts believe statewide standing/protocol orders are an effective, implementable, and equitable policy for addressing opioid-related overdose mortality. While experts believe many other broad policies are effective in reducing opioid-related harms, they also believe these policies face implementation challenges related to cost and reaching vulnerable populations.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Harm reduction; Mortality; Naloxone; Opioids; Overdose; Pharmacy

Mesh:

Substances:

Year:  2021        PMID: 34340167      PMCID: PMC8671224          DOI: 10.1016/j.drugpo.2021.103383

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  58 in total

1.  Good Samaritan harm reduction policy and drug overdose deaths.

Authors:  Danielle N Atkins; Christine Piette Durrance; Yuna Kim
Journal:  Health Serv Res       Date:  2019-02-11       Impact factor: 3.402

2.  Beliefs Associated with Pharmacy-Based Naloxone: a Qualitative Study of Pharmacy-Based Naloxone Purchasers and People at Risk for Opioid Overdose.

Authors:  Elizabeth Donovan; Patricia Case; Jeffrey P Bratberg; Janette Baird; Dina Burstein; Alexander Y Walley; Traci C Green
Journal:  J Urban Health       Date:  2019-06       Impact factor: 3.671

3.  Using the behaviour change wheel to understand and address barriers to pharmacy naloxone supply in Australia.

Authors:  Suzanne Nielsen; Anna Olsen
Journal:  Int J Drug Policy       Date:  2020-12-11

4.  Availability of Naloxone at Rural Georgia Pharmacies, 2019.

Authors:  Jennifer L Nguyen; Lauren R Gilbert; Lauren Beasley; John J Brooks; Jennifer Elliott; K Bryant Smalley; Jacob C Warren
Journal:  JAMA Netw Open       Date:  2020-02-05

5.  Pharmacists' role in opioid overdose: Kentucky pharmacists' willingness to participate in naloxone dispensing.

Authors:  Patricia R Freeman; Amie Goodin; SuZanne Troske; Audra Strahl; Amanda Fallin; Traci C Green
Journal:  J Am Pharm Assoc (2003)       Date:  2017-01-28

6.  Why aren't Australian pharmacists supplying naloxone? Findings from a qualitative study.

Authors:  Anna Olsen; Belinda Lawton; Robyn Dwyer; Meng-Wong Taing; Ka Lai Joyce Chun; Samantha Hollingworth; Suzanne Nielsen
Journal:  Int J Drug Policy       Date:  2019-05-09

7.  We Need a Taxonomy of State-Level Opioid Policies.

Authors:  Sean Grant; Rosanna Smart; Bradley D Stein
Journal:  JAMA Health Forum       Date:  2020-02-05

8.  Acceptability and feasibility of naloxone prescribing in primary care settings: A systematic review.

Authors:  Emily Behar; Rita Bagnulo; Phillip O Coffin
Journal:  Prev Med       Date:  2018-06-15       Impact factor: 4.018

9.  Racial inequities in U.S. naloxone prescriptions.

Authors:  Erin Fanning Madden; Fares Qeadan
Journal:  Subst Abus       Date:  2019-11-13       Impact factor: 3.716

10.  Prioritizing Needs and Outcomes for Adolescent Substance Use Treatment Planning: An Online Modified-Delphi Process.

Authors:  Sean Grant; Eric R Pedersen; Sarah B Hunter; Dmitry Khodyakov; Beth Ann Griffin
Journal:  J Addict Med       Date:  2020 Jul/Aug       Impact factor: 3.702

View more
  2 in total

1.  Priority setting for Canadian Take-Home Naloxone best practice guideline development: an adapted online Delphi method.

Authors:  Max Ferguson; Andrea Medley; Katherine Rittenbach; Thomas D Brothers; Carol Strike; Justin Ng; Pamela Leece; Tara Elton-Marshall; Farihah Ali; Diane L Lorenzetti; Jane A Buxton
Journal:  Harm Reduct J       Date:  2022-07-02

2.  Expert views on state-level naloxone access laws: a qualitative analysis of an online modified-Delphi process.

Authors:  Sean Grant; Rosanna Smart
Journal:  Harm Reduct J       Date:  2022-06-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.